Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
· financialcontent
AI Briefing
- • Caribou Biosciences reports positive CB-011 dose escalation durability data at the 2026 EHA Annual Meeting.
- • CB-011 shows 83% CR rate, 91% MRD negativity, and 50% ≥CR at 15 months in MM patients.
- • Data available only to subscribers of the paid plan.
Source Summary
-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months --
Advertisement